Skip to main content

emergent-biosolution-logo

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine Vivotif® (Typhoid Vaccine Live Oral Ty21a) in five additional European Union Member States, including France, Portugal, Poland, Czech Republic and Slovakia as well as approval of harmonized prescribing information in the EU also known as the Summary of Product Characteristics or SmPC.

{iframe}https://www.globenewswire.com/news-release/2019/05/20/1829180/0/en/Emergent-BioSolutions-Announces-Granting-of-Marketing-Authorization-in-Five-EU-Countries-for-Its-Oral-Typhoid-Vaccine-Expands-Availability-Across-Europe.html{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.